Halozyme Therapeutics, Inc. — FY 2018 Form 10-K
Reporting period: Fiscal year ended December 31, 2018. The filing also reports unaudited fourth-quarter results. Amounts are in U.S. dollars unless noted.
Business context
Halozyme is a biotechnology company with two main activities: developing oncology therapies, especially PEGPH20, and licensing its ENHANZE rHuPH20 drug-delivery technology to biopharmaceutical partners. Its marketed products include Hylenex and partnered ENHANZE products. Most revenue comes from royalties, partner licenses and milestones, and sales of bulk rHuPH20; results therefore depend substantially on partners’ development and commercial performance.
Financial performance and liquidity
| Metric | FY 2018 | FY 2017 |
|---|---|---|
| Total revenue | $151.9 million | $316.6 million |
| Operating income (loss) | ($69.3 million) | $81.0 million |
| Net income (loss) | ($80.3 million) | $63.0 million |
| Diluted earnings (loss) per share | ($0.56) | $0.45 |
| Net cash from (used in) operating activities | ($49.5 million) | $134.1 million |
| Cash, cash equivalents and marketable securities at year-end | $354.5 million | $469.2 million |
| Working capital at year-end | $278.5 million | $379.0 million |
| Long-term debt, net, current and non-current | $126.4 million | $202.4 million |
FY 2018 royalties were $79.0 million, up from $63.5 million, supported by partner sales of Roche’s Herceptin SC and MabThera SC/RITUXAN HYCELA and Baxalta’s HYQVIA. Product sales fell to $28.2 million from $50.4 million, mainly because Roche and Baxalta reduced bulk rHuPH20 purchases while drawing down inventory ahead of manufacturing transitions. Collaborative-agreement revenue fell to $44.6 million from $202.7 million, largely reflecting substantially lower upfront and milestone revenue than in 2017.
Research and development expense was $150.3 million, approximately flat year over year; PEGPH20 accounted for $131.1 million and increased 6%. Selling, general and administrative expense rose 13% to $60.8 million. Interest expense was $18.0 million. In 2018, operating and financing cash outflows were $49.5 million and $63.8 million, respectively; financing cash use included $77.5 million of debt repayments. The company reported $91.5 million of current debt and $34.9 million of long-term debt, net. Management said existing cash and investments should fund operations for at least 12 months.
Fourth-quarter 2018 revenue was $60.2 million and net loss was $2.1 million. Q4 revenue included $30.0 million recognized under a Roche collaboration arrangement.
Material changes and notable developments
- Revenue declined 52% year over year and results moved from profit to loss, primarily because 2017 included large collaboration license and milestone payments, including BMS, Alexion and Janssen payments.
- Operating cash flow swung from positive $134.1 million in 2017 to negative $49.5 million in 2018, reflecting lower earnings and working-capital changes, including increased inventory.
- Cash and marketable securities declined by $114.7 million from year-end 2017; net debt declined as scheduled repayments reduced borrowings.
- Halozyme adopted ASC 606 in 2018 using the modified retrospective approach. The adoption increased opening accumulated earnings by $71.3 million and reduced reported 2018 revenue by $4.7 million. Prior-year revenue was not restated, so year-over-year comparisons are affected by different accounting policies.
- HALO-301, a Phase 3 PEGPH20 trial in HA-high, stage IV pancreatic cancer, completed enrollment of approximately 500 patients by year-end. The FDA agreed to make overall survival the single primary endpoint; progression-free survival remains secondary. Management projected the target 330 overall-survival events would be reached between August and November 2019.
Outlook, risks and contingencies
- Management expected PEGPH20 research and development spending to increase in the near term as clinical programs advance, and expected SG&A to rise as the company prepares for a potential commercial launch. ENHANZE-related R&D spending was also expected to increase to support partners. These are expectations, not assured outcomes.
- Management expected royalty revenue to increase over time with partner product sales, while noting that royalties can vary; bulk rHuPH20 sales may fluctuate and Hylenex sales were expected to be flat or decline amid competition.
- Clinical and regulatory outcomes remain uncertain. In a separate SWOG trial, the PEGPH20 plus modified FOLFIRINOX arm was stopped after a futility analysis; reported median overall survival was 7.7 months versus 14.4 months for chemotherapy alone, with greater gastrointestinal toxicity. The filing says other PEGPH20 studies continued.
- Key risks include reliance on collaborators and a concentrated revenue base: Roche represented 72% of FY 2018 revenue. The company also depends on third-party manufacturers, has a history of losses and negative operating cash flow, and may need additional capital if cash and future receipts are insufficient.
- Debt includes a royalty-backed loan bearing 8.75% plus three-month LIBOR and a secured loan bearing 8.25%. The company estimated repayment of the royalty-backed loan in Q1 2020, conditional on royalty receipts; lower-than-expected receipts could extend repayment. It reported compliance with debt covenants at year-end.
- No legal proceedings were reported that management believed would have a material adverse effect. Management and the independent auditor concluded internal control over financial reporting was effective as of December 31, 2018.
Subsequent event: In February 2019, Halozyme signed an argenx ENHANZE agreement for a $30.0 million upfront payment, potential additional target fees and milestones, and mid-single-digit royalties on commercial sales.
Investor facts to verify
- HALO-301’s overall-survival event timing, final results, and any regulatory implications of the endpoint change.
- Partner product sales, royalty growth, and Roche’s continuing share of revenue, including the effects of collaborator inventory and manufacturing transitions.
- Cash burn, liquidity runway, planned PEGPH20 and commercial-preparation spending, and whether additional financing may be needed.
- Debt repayment progress and the sensitivity of the royalty-backed loan schedule to partner royalty receipts and interest rates.
- Clinical safety and efficacy developments across PEGPH20 programs, including the significance of the SWOG results and the status of other trials.